Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (5122)	12/15/1997 7:18:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

First, let me point out, its all speculation on my part too. Also I have no expertise in this area. Cacaito, I very much appreciate your "take" on it, but I think you missed my point regarding bpi/anca/cf. In CF patients natural bpi apparently doesnt function well because of ANCA. Administering natural or rbpi may help the body to overcome infection. If in fact (and we dont know) its true that ANCA only reacts with the c-terminal portion,then ANCA should be non-reactive to rbpi21. (I know wording isnt right, but you get the idea). Therefore rbpi21 may exert a effect without(too much) fear of anca negating its effect. A further comment or comments are appreciated as I am speculating here. Let me further point out that cf trial is off to a slow start and we have no idea whether it will be of benefit or not. Or even if the pharmokinetics will be acceptable. Tharos-hope your buying pushes it over 10 :-)